Specific Knockdown of α-Synuclein by Peptide-Directed Proteasome Degradation Rescued Its Associated Neurotoxicity
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A peptide-based α-synuclein degrader has been reported and was shown to protect neurons from α-synuclein overexpression-induced toxicity.
“A peptide-based α-synuclein degrader (see below) has been reported and was shown to protect neurons from α-synuclein overexpression-induced toxicity193.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [193]
Multiple groups have described a range of pepTACs that harness SKP1/SCF F-box, VHL, KEAP1 and other E3 ligases to degrade tau or α-synuclein in primary neurons and other cell lines.
“Additionally, multiple groups have described a range of pepTACs that harness SKP1/SCF F-box, VHL, KEAP1 and other E3 ligases to degrade tau or α-synuclein in primary neurons and other cell lines188,193,213”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [193]
Cited by
Sorted by citations
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395 · see citing works
Zhang, B., Brahma, R. K., Zhu, L., Feng, J., Hu, S., Qian, L., Du, S., Yao, S. Q., & Ge, J. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c08886 · Cited by 85 · see citing works
Kurrikoff, K., Vunk, B., & Langel, Ü. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1823368 · Cited by 82 · see citing works
Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
Wang, H., Zhou, R., Xu, F., Yang, K., Zheng, L., Zhao, P., Shi, G., Dai, L., Xu, C., Yu, L., et al. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00385-8 · Cited by 46 · see citing works
Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials
Liu, M., Wang, Z., & Shang, H. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12269-5 · Cited by 34 · see citing works
The YΦ motif defines the structure-activity relationships of human 20S proteasome activators
Opoku-Nsiah, K., de la Peña, A. H., Williams, S. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28864-x · Cited by 25 · see citing works
Andrés, C. M. C., Lobo, F., de la Lastra, J. M. P., Munguira, E. B., Andrés, C., & Lebeña, E. P. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090765 · Cited by 25 · see citing works
Ge, R., Chen, M., Li, Q., Liu, M., Zhou, J., & Xie, S. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01538-2 · Cited by 13 · see citing works
Benyair, R., Giridharan, S. S. P., Rivero-Ríos, P., Hasegawa, J., Bristow, E., Eskelinen, E., Shmueli, M. D., Fishbain-Yoskovitz, V., Merbl, Y., Sharkey, L. M., et al. (2023) · Autophagy Reports · doi:10.1080/27694127.2023.2166722 · Cited by 13 · see citing works
Liu, M., Chen, J., Li, H., Ma, Y., Xiao, Q., Ding, J., Li, J., & Chen, X. (2026) · Chemical Society Reviews · doi:10.1039/d5cs01504a · Cited by 14 · see citing works
PROTAC technology for prostate cancer treatment
Wang, Z., Zhang, D., Inuzuka, H., & Wei, W. (2025) · Acta Materia Medica · doi:10.15212/amm-2024-0075 · Cited by 9 · see citing works
“In 2020, Qu et al. [159] introduced another TAT-PBD-PTM based on peptides that specifically targets and degrades α -synuclein in Parkinson’s disease [159].”
Langel, Ü. (2023) · Springer eBooks · doi:10.1007/978-3-031-38731-9_7
Sprayable androgen receptor PROTAC degrader for immunomodulation and accelerated skin regeneration
Jang, S. Y., Park, B., Ko, E., 신동원, Jang, Y., Lee, W. S., Lee, J.-H., Lee, A., Park, J., Lee, S. P., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.179954
- Authors
- Qu, J., Ren, X., Xue, F., He, Y., Zhang, R., Zheng, Y., Huang, H., Wang, W., & Zhang, J.
- Corresponding author
- Zhang, Jianliang
- Venue
- Cell Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 27
- Issue
- 6
- Pages
- 763
- ISSN
- 2451-9448 (ISSN-L)
- 2451-9456
- OpenAlex
- W4237371248
- Cited by
- 13
- References
- 0
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2023: 4 · 2022: 2 · 2020: 1
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell chemical biology (publishedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- alpha-synuclein, proteasomal degradation, Parkinson's disease, neurotoxicity, cell-penetrating peptides, fusion peptide, intrinsically disordered proteins, protein degradation, neuroprotection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
